Schwab Andrew J.'s Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Sep 28, 2023
- Accession no.
- 0001209191-23-050731
- Filed
- Sep 28, 2023, 4:27 PM ET
- Trade date
- Sep 26, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $2.96M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schwab Andrew J.CIK 0001598549 | 10% Owner |
| Parmar KushCIK 0001664281 | 10% Owner |
| 5AM Opportunities I, L.P.CIK 0001753000 | 10% Owner |
| 5AM Ventures VI, L.P.CIK 0001753037 | 10% Owner |
| 5AM Opportunities I (GP), LLCCIK 0001790778 | 10% Owner |
| 5AM Partners VI, LLCCIK 0001829051 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2023 | Common Stock | SSaleDisposed | −164,789 | $15.00 | −$2,471,835 | 4,306,179 | Indirect | |
| Sep 26, 2023 | Common Stock | SSaleDisposed | −32,711 | $15.00 | −$490,665 | 854,796 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.